Wedbush Reaffirms Outperform Rating for Xoma Corp. (XOMA)
Xoma Corp. (NASDAQ:XOMA)‘s stock had its “outperform” rating reissued by analysts at Wedbush in a report issued on Wednesday. They presently have a $17.00 price objective on the stock. Wedbush’s price target would indicate a potential upside of 172.44% from the company’s current price.
A number of other research firms have also recently commented on XOMA. Jefferies Group reissued a “hold” rating on shares of Xoma Corp. in a research note on Friday, August 5th. Zacks Investment Research raised Xoma Corp. from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research note on Wednesday, August 10th. Finally, Cowen and Company reissued a “neutral” rating on shares of Xoma Corp. in a research note on Wednesday, August 10th. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Xoma Corp. currently has a consensus rating of “Hold” and an average target price of $4.61.
Shares of Xoma Corp. (NASDAQ:XOMA) traded down 16.554% on Wednesday, reaching $5.207. The company’s stock had a trading volume of 290,083 shares. The firm has a market cap of $627.88 million, a price-to-earnings ratio of 473.364 and a beta of 2.87. The stock has a 50 day moving average of $0.68 and a 200-day moving average of $0.67. Xoma Corp. has a 12 month low of $0.34 and a 12 month high of $7.33.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/19/wedbush-reaffirms-outperform-rating-for-xoma-corp-xoma.html
Xoma Corp. (NASDAQ:XOMA) last released its quarterly earnings results on Wednesday, August 3rd. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.01. The firm had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.84 million. During the same quarter in the prior year, the firm posted ($0.20) earnings per share. On average, analysts anticipate that Xoma Corp. will post ($0.47) EPS for the current year.
Several hedge funds have recently bought and sold shares of XOMA. Spark Investment Management LLC raised its stake in Xoma Corp. by 100.9% in the second quarter. Spark Investment Management LLC now owns 203,900 shares of the company’s stock worth $112,000 after buying an additional 102,400 shares in the last quarter. Bellevue Group AG acquired a new position in shares of Xoma Corp. during the first quarter worth $174,000. Paloma Partners Management Co acquired a new position in shares of Xoma Corp. during the second quarter worth $185,000. Wedbush Securities Inc. increased its position in shares of Xoma Corp. by 4.1% in the second quarter. Wedbush Securities Inc. now owns 404,396 shares of the company’s stock worth $223,000 after buying an additional 15,827 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new position in shares of Xoma Corp. during the first quarter worth $374,000. Institutional investors own 17.13% of the company’s stock.
About Xoma Corp.
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Ratings for Xoma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xoma Corp. and related companies with MarketBeat.com's FREE daily email newsletter.